OncLive On AirTM is a podcast from OncLive® that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays.
September 14th 2021
In the second segment, Dr Pegram and colleagues discuss the clinical implications of the data from select trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.
September 14th 2021
In the first segment, Dr Pegram and colleagues highlight some of the challenges and remaining unmet needs in the management of patients with HER2-positive breast cancer.
September 13th 2021
Dr. Loaiza-Bonilla discusses approaches to frontline treatment selection in metastatic pancreatic cancer, the effects of adverse effects and toxicities in treatment planning, and treatment options available to patients post gemcitabine-based regimens.
September 9th 2021
Lisberg discusses the excitement with datopotamab deruxtecan in non–small cell lung cancer and previews anticipated data from the NSCLC cohort of the TROPION-PanTumor01 trial at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer.
September 6th 2021
Dr. McKay discusses the importance of patient selection in advanced renal cell carcinoma, selecting between available combination regimens, and nuances regarding the timing of treatment in this disease.
September 2nd 2021
Dr. Sosa discusses the rise in thyroid cancer cases, patient risk factors, the financial challenges associated with long-term treatment and testing, and future research directions in the field.
August 30th 2021
Dr. Sekeres discusses the current unmet needs of patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents, the potential utility of novel combinations in development, and the incorporation of other end points beyond overall survival in clinical trials.
August 26th 2021
Dr. Janjigian discusses the FDA approval of nivolumab plus chemotherapy in advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, key findings from the pivotal CheckMate-649 trial, and future directions with immunotherapy in the field.
August 23rd 2021
Dr. Krie and Dr. Yuan discussed treatment-related adverse effects one should be aware of and prepared to manage, recommended management strategies for these TRAEs, and important points to emphasize to patients before they begin treatment.
August 19th 2021
Dr. Labaki and Dr. Trinh discuss their research on the recovery of cancer screening tests, its link with potential racial disparities from the COVID-19 pandemic, and how the community can continue to emphasize the importance of cancer screening while working to close these disparities in cancer care.
August 16th 2021
Dr. Chachoua discusses key guidelines for lung cancer screening, the psychological and financial implications of screening, and the opportunities of a screening initiative instated by NYU Langone Health.
August 12th 2021
Drs. Brown and Kurzrock discuss the current and future applications of next-generation sequencing in breast cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.
August 9th 2021
Dr. Moreau discusses the FDA approval of isatuximab-irfc plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma, key findings from the pivotal IKEMA trial, and future directions with the combination.
August 5th 2021
Dr. Weber discusses exciting research presented during the 2021 ASCO Annual Meeting in melanoma with combination and single-agent checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and more.
August 2nd 2021
Chevon M. Rariy, MD, discusses how the implementation of telehealth during the COVID-19 pandemic shed light on the need for increased access to care for patients with cancer, as well as the potential benefits in-home infusions could offer to patients receiving chemotherapy.
July 29th 2021
Dr. George and Dr. Hurley discuss the data generated from their study on the correlation between deleterious variants in genes and the development of hereditary breast and ovarian cancers in populations throughout the Caribbean.
July 28th 2021
Dr Mahtani and colleagues highlight key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.
July 28th 2021
In the second segment, Dr Mahtani and colleagues discuss data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.
July 28th 2021
In the first segment, Dr Mahtani and colleagues outline challenges and remaining unmet needs in the management of patients with HER2-positive breast cancer.
July 26th 2021
Drs Brown and Husain discuss the current and future applications of next-generation sequencing in lung cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.